Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Sintilimab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Innovent Biologics (Suzhou) Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Sintilimab is an immunotherapy drip used for several cancers, from Hodgkin lymphoma to lung, liver, oesophageal and stomach cancer. It is made in China by Innovent Biologics (Suzhou) Co., Ltd., which developed it together with Eli Lilly, and it is sold there under the brand name TYVYT® (达伯舒).
China's National Medical Products Administration (NMPA) first approved it in December 2018 for classical Hodgkin lymphoma. The current Chinese label lists these uses:
Which use applies to a patient depends on the exact cancer type and test results, so the decision rests with the treating oncologist. You can read more about the cancers we support on our oncology medicines page.
Cancer cells often protect themselves by switching on a "brake" on the immune system called PD-1, which sits on T cells. This medicine is a fully human IgG4 monoclonal antibody that sticks to PD-1 and blocks that brake, so the patient's own T cells can recognise and attack the tumour again. Because it acts through the immune system, its side effects are different from those of chemotherapy and can appear weeks or months into treatment.
According to the Chinese label:
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Immune-related side effects: by releasing the brake on the immune system, this antibody can cause the immune system to attack healthy organs. These reactions can be serious and, rarely, fatal. They may start during treatment or after it has stopped. Most settle when the drip is paused and steroids are given, so early reporting matters.
Common side effects when used alone (568 patients): anaemia 34.5%, fever 26.8%, abnormal thyroid tests 20.6%, raised liver enzymes (ALT and AST) 19.0% each, protein in the urine 17.4% and tiredness 16.5%. Severe (grade 3 or higher) reactions occurred in 30.3%. When combined with chemotherapy, low blood counts, nausea and loss of appetite were more frequent.
Pregnancy and breastfeeding: it is not advised in pregnancy unless the benefit clearly outweighs the risk. Women and men of child-bearing potential should use effective contraception during treatment and for at least 5 months after the last dose, and breastfeeding should stop for the same period. Safety in people under 18 has not been established. Steroids or other immune-suppressing medicines should ideally be avoided before starting, as they may reduce the effect.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Supply is arranged only for a named patient, by the patient or a hospital, following India's rules for importing unapproved medicines. The usual papers are:
After we have reviewed a valid prescription and, where required, the import permit has been granted.
No. It has no CDSCO marketing approval and is not sold in Indian pharmacies. An Indian company has sought permission only to run clinical trials here, which is not the same as approval. In the United States, the FDA declined to approve it for lung cancer in March 2022, so it is not FDA approved either.
Doctors can still request it through the Named Patient Program (NPP), a legal route for one patient to receive a medicine that is not registered in India. We also support access to other China-approved immunotherapies such as ivonescimab and adebrelimab.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The vials must stay refrigerated at 2°C to 8°C in their original carton, away from light, and must not be frozen or shaken. They are therefore moved under temperature-controlled shipping from the source right up to the hospital pharmacy. Since a standard dose uses two vials every three weeks, we plan each shipment around the patient's infusion dates. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
This immunotherapy can be supplied to patients across India through regulated import routes, with refrigerated delivery to the treating hospital on a valid oncologist's prescription.
Large cancer centres in the capital see many lung and stomach cancer patients, and dispatch from New Delhi keeps the refrigerated transit time short.
Oncologists in Mumbai can share the prescription and biopsy reports with us, and the vials are delivered to the hospital before the planned infusion day.
We coordinate with day-care chemotherapy units in Bangalore so the antibody arrives in time to be given ahead of the chemotherapy.
Hospitals in Chennai that treat lymphoma and liver cancer can receive the drip vials in sealed, temperature-logged packs.
For patients on a three-weekly schedule in Hyderabad, we can line up each shipment with the next treatment cycle.
Deliveries to Kolkata and the north-east are routed to keep the vials between 2°C and 8°C throughout.
Families in Pune get a written quote first and status updates as the import moves forward.
The treating oncologist in Ahmedabad can start the request by sending the prescription and test reports to our team.
Patients treated in Vellore can have the medicine delivered straight to the hospital pharmacy for each cycle.
We serve patients from Punjab, Haryana and Himachal Pradesh with delivery to their treating hospital in Chandigarh.
Cancer hospitals across Uttar Pradesh can receive cold-chain deliveries through Lucknow.
Patients in Kerala can receive the infusion vials at their hospital in Kochi or a nearby city.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 18 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message